{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:01:41Z","timestamp":1790096501478,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"DOI":"10.1007\/s00428-026-04722-9","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:48:39Z","timestamp":1790048919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Interchangeability of 22C3 and 28\u2009\u2212\u20098 PD-L1 assays for patient selection in esophageal squamous cell carcinoma"],"prefix":"10.1007","author":[{"given":"Halim","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Seon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uiree","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-4254","authenticated-orcid":false,"given":"Joon Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"4722_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4722_CR2","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMra1314530","volume":"371","author":"AK Rustgi","year":"2014","unstructured":"Rustgi AK, El-Serag HB (2014) Esophageal carcinoma. N Engl J Med 371:2499\u20132509. https:\/\/doi.org\/10.1056\/NEJMra1314530","journal-title":"N Engl J Med"},{"key":"4722_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I (2020) Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69:1564\u20131571. https:\/\/doi.org\/10.1136\/gutjnl-2020-321600","journal-title":"Gut"},{"key":"4722_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M (2022) The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology 163:649\u2013658e2. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.054","journal-title":"Gastroenterology"},{"key":"4722_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP and Group CW (2018) Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3","journal-title":"Lancet"},{"key":"4722_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, Tervonen H, Thursfield V, Ransom D, Shack L, Woods RR, Turner D, Leonfellner S, Ryan S, Saint-Jacques N, De P, McClure C, Ramanakumar AV, Stuart-Panko H, Engholm G, Walsh PM, Jackson C, Vernon S, Morgan E, Gavin A, Morrison DS, Huws DW, Porter G, Butler J, Bryant H, Currow DC, Hiom S, Parkin DM, Sasieni P, Lambert PC, Moller B, Soerjomataram I, Bray F (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493\u20131505. https:\/\/doi.org\/10.1016\/S1470-2045(19)30456-5","journal-title":"Lancet Oncol"},{"key":"4722_CR7","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D (2017) Oesophageal cancer. Nat Rev Dis Primers 3:17048. https:\/\/doi.org\/10.1038\/nrdp.2017.48","journal-title":"Nat Rev Dis Primers"},{"key":"4722_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC (2021) The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600:727\u2013730. https:\/\/doi.org\/10.1038\/s41586-021-04161-3","journal-title":"Nature"},{"key":"4722_CR9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, Shen M, Ruan S, Wasan HS, Qiu S (2020) Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 10:2083. https:\/\/doi.org\/10.1038\/s41598-020-58674-4","journal-title":"Sci Rep"},{"key":"4722_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K, Investigators K- (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"4722_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y, CheckMate 648 Trial I (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"4722_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH (2023) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 24:483\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0","journal-title":"Lancet Oncol"},{"key":"4722_CR13","unstructured":"European Medicines Agency (2026) Keytruda (pembrolizumab): EPAR product information. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed 14 July 2026"},{"key":"4722_CR14","unstructured":"US Food and Drug Administration (2026) KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125514s187lbl.pdf. Accessed 14 July 2026"},{"key":"4722_CR15","unstructured":"European Medicines Agency (2026) Opdivo (nivolumab): EPAR product information. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed 14 July 2026"},{"key":"4722_CR16","unstructured":"US Food and Drug Administration (2026) OPDIVO\u00ae (nivolumab) injection, for intravenous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125554s136lbl.pdf. Accessed 14 July 2026"},{"key":"4722_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaoncol.2022.5816","volume":"9","author":"DWT Yap","year":"2023","unstructured":"Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, Pietrantonio F (2023) Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups. JAMA Oncol 9:215\u2013224. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5816","journal-title":"JAMA Oncol"},{"key":"4722_CR18","unstructured":"US Food and Drug Administration (2026) List of cleared or approved companion diagnostic devices (in vitro and imaging tools). https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools. Accessed 14 July 2026"},{"key":"4722_CR19","unstructured":"US Food and Drug Administration (2026) PD\u2013L1 IHC 28\u20138 pharmDx: Premarket Approval (PMA P150025 and supplements). Premarket Approval database record. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P150025S018. Accessed 14 July 2026"},{"key":"4722_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/jclinpath-2018-205362","volume":"71","author":"C Batenchuk","year":"2018","unstructured":"Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V (2018) A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28\u2009\u2013\u20098 and 22C3 in lung cancer and other malignancies. J Clin Pathol 71:1078\u20131083. https:\/\/doi.org\/10.1136\/jclinpath-2018-205362","journal-title":"J Clin Pathol"},{"key":"4722_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/jclinpath-2020-206466","volume":"73","author":"GS Krigsfeld","year":"2020","unstructured":"Krigsfeld GS, Prince EA, Pratt J, Chizhevsky V, William Ragheb J, Novotny J Jr., Huron D (2020) Analysis of real-world PD-L1 IHC 28\u2009\u2013\u20098 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. J Clin Pathol 73:656\u2013664. https:\/\/doi.org\/10.1136\/jclinpath-2020-206466","journal-title":"J Clin Pathol"},{"key":"4722_CR22","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.21037\/jgo-21-505","volume":"12","author":"Y Narita","year":"2021","unstructured":"Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, Yatabe Y, Muro K (2021) PD-L1 immunohistochemistry comparison of 22C3 and 28\u2009\u2013\u20098 assays for gastric cancer. J Gastrointest Oncol 12:2696\u20132705. https:\/\/doi.org\/10.21037\/jgo-21-505","journal-title":"J Gastrointest Oncol"},{"key":"4722_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcm.2016.02.012","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012. 15:155\u2009\u2013\u200963","journal-title":"J Chiropr Med"},{"key":"4722_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-13-61","volume":"13","author":"N Wongpakaran","year":"2013","unstructured":"Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL (2013) A comparison of Cohen\u2019s Kappa and Gwet\u2019s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med Res Methodol 13:61. https:\/\/doi.org\/10.1186\/1471-2288-13-61","journal-title":"BMC Med Res Methodol"},{"key":"4722_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1348\/000711006X126600","volume":"61","author":"KL Gwet","year":"2008","unstructured":"Gwet KL (2008) Computing inter-rater reliability and its variance in the presence of high agreement. Br J Math Stat Psychol 61:29\u201348. https:\/\/doi.org\/10.1348\/000711006X126600","journal-title":"Br J Math Stat Psychol"},{"key":"4722_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","volume":"25","author":"J Yeong","year":"2022","unstructured":"Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, Choo JR, Jeyasekharan AD, Miow QH, Loo LH, Yong WP, Sundar R (2022) Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 25:741\u2013750. https:\/\/doi.org\/10.1007\/s10120-022-01301-0","journal-title":"Gastric Cancer"},{"key":"4722_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","volume":"34","author":"S Ahn","year":"2021","unstructured":"Ahn S, Kim KM (2021) PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28\u2009\u2013\u20098 pharmDx assays for responses to immunotherapy. Mod Pathol 34:1719\u20131727. https:\/\/doi.org\/10.1038\/s41379-021-00823-9","journal-title":"Mod Pathol"},{"key":"4722_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.pathol.2024.06.006","volume":"56","author":"JS Jeong","year":"2024","unstructured":"Jeong JS, Jo U, Choi G, Song H, Cho KJ, Song JS (2024) Comparison of PD-L1 assays in head and neck carcinoma. Pathology 56:969\u2013981. https:\/\/doi.org\/10.1016\/j.pathol.2024.06.006","journal-title":"Pathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04722-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04722-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04722-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:03:19Z","timestamp":1790092999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04722-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":28,"alternative-id":["4722"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04722-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of Asan Medical Center (IRB No. 2025-0107) approved the study before starting data collection, and the study was performed in accordance with the committee guidelines and regulations. The requirement for informed consent was waived by the board.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}